Latest Breaking News On - Mario lacouture - Page 3 : comparemela.com

Share this article Share this article SAN DIEGO, March 3, 2021 /PRNewswire/  Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication, commented Saiid Zarrabian, Kintara s Chief Executive Officer. We look forward to working closely with Dr. Lacouture, utilizing his experience as a leading expert in the treatment of CMBC to ensure REM-001 s pivotal clinical trial is optimally designed and executed.

New yorkUnited statesMemorial sloan kettering cancer centerSan diegoMario lacoutureJules abrahamCompany current reports on formKintara therapeutics incCompany quarterly reports on formCompany annual report on formJaveriana universityUniversity of chicagoOncodermatology programKintara therapeuticsAdvisory boardCutaneous metastatic breast cancer